Skip to Content

Apnimed makes critical additions to C-suite 

Apnimed makes critical additions to C-suite 

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacological therapies for the treatment of obstructive sleep apnea and related disorders, has named Graham Goodrich as chief commercial officer and Ted Harding as chief human resources officer. The company says the additions to the C-suite are critical as the company prepares to launch AD109, a potential nighttime oral treatment currently in Phase 3. “We are thrilled to have attracted two senior executive leaders with the ability to drive and manage change as we build our commercial capabilities for AD109,” said Dr. Larry Miller, CEO of Apnimed. 

  • Recently, as a member of the commercial leadership team and senior vice president of Migraine Market at Biohaven, Goodrich led a team that developed a novel brand strategy, go-to-market model and promotion plan to launch Nurtec ODT during the COVID-19 pandemic. After a successful launch and achieving category leadership, Pfizer acquired the Biohaven Migraine franchise assets and capabilities in October 2022 for $11.6 billion. 

  • Harding is a senior executive leader who has guided and built the culture and human resources infrastructure at biotech companies that have included Jounce Therapeutics and Enobia Pharma. He has been the head of human resources for 10 companies on either a full-time or interim basis, and has prior experience in the electric utility, telecommunications, and clean energy sectors.   


To comment on this post, please log in to your account or set up an account now.